Bristol Myers Squibb, being a larger entity with a diversified portfolio, may see a positive impact from the growth of Abecma, but the overall importance to the company's bottom line may be less compared to 2seventy bio. The confidence level reflects the uncertainty of the future market conditions and the effectiveness of the growth strategies.

As 2seventy bio is directly involved in the partnership and growth strategy for Abecma, the news is highly relevant and important to the company. The positive impact on commercial growth is likely to be seen as a positive by investors, hence the positive score. The confidence level is not at the maximum because the actual financial impact will depend on the success of the growth strategies implemented.